Atsena Therapeutics Appoints Jennifer Wellman to Board of Directors (Globe Newswire)

Atsena Therapeutics Appoints Jennifer Wellman to Board of Directors

UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, announced the appointment of Jennifer Wellman to its board of directors. Ms. Wellman, a biotech executive with more than 20 years of gene therapy development experience, will serve as an independent director.

“Jen’s extensive U.S. and EU regulatory expertise and impressive track record in the clinical development of AAV-based gene therapies are valuable to Atsena as we progress cutting-edge gene therapies designed to overcome the hurdles presented by inherited retinal disease,” said Patrick Ritschel, MBA, chief executive officer of Atsena. “We’re thrilled to welcome Jen to Atsena’s board of directors and look forward to leveraging her strategic insights.”

Learn more about Atsena Therapeutics Appoints Jennifer Wellman to Board of Directors.
X